Resistance to therapy is the major hurdle in the current cancer management. Cancer cells
often rewire their cellular process to alternate mechanisms to resist the deleterious effect …

For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …

The Notch signaling pathway is an architecturally simple signaling mechanism, well known
for its role in cell fate regulation during organ development and in tissue homeostasis. In …

While first line targeted therapies are the current standard of care treatment for non-small
cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire …

Introduction S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP)
evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome …

Background Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in
patients with many types of cancer. Genomic mutations may be used to predict the clinical …

Abstract Immune-checkpoint inhibitors (ICIs), different from traditional cancer treatment
models, have shown unprecedented anti-tumor effects in the past decade, greatly improving …

Notch signaling pathway is a highly conserved system of cell-to-cell communication that
participates in various biological processes, such as stem cell maintenance, cell fate …

Simple Summary Cancers in the head and neck region are often aggressive and poorly
respond to both irradiation or chemotherapy. Chemotherapy is currently limited by a small …

Objectives Non-small cell lung cancer (NSCLC) with brain metastases (BM) is a challenging
clinical issue with poor prognosis. No data exist regarding extensive genetic analysis of …